For Providers

Creating Sustainability & Longevity for Biosimilars

At AmerisourceBergen, we believe in the promise of biosimilars to deliver cost savings across healthcare. We also understand the potential hurdles these unique products will face. That's why we offer solutions for increasing access to and confidence in these emerging therapies.

Defining biosimilars

What are biosimilars? 

Biosimilars are biologics that are highly similar — yet not identical — to a reference product. Before a biosimilar goes to market, its manufacturer must conduct studies to show it is highly similar to the reference product. Biosimilar products go through a rigorous FDA approval process to make sure they are safe, pure, and effective. From a clinical perspective, there is no meaningful difference between a reference product and its biosimilar.

What is the difference between generics and biosimilars? 

Biosimilars are not generics. Generics are exact copies of synthetic pharmaceuticals and the active ingredients must be the same as a brand name drug. Biosimilars are copies of biologics, which are medications made with living cells. They can have slight differences in clinically inactive components. The important thing to remember is there is no difference in how a biosimilar and its reference product treats your patients’ conditions.

What to know about biosimilars

Providers and pharmacists 

As a provider, you make choices every day about what medications to prescribe or recommend. A biosimilar and its reference product will provide the same clinical results for your patients. We want you to feel confident in your decision to pick biosimilars for your patients. We are here to support you with innovative solutions to help increase access to emerging therapies, like biosimilars. You can help drive long-term stability in the biosimilars market. We provide easier access to biosimilars entering the market so you can make the best choice for your patients' care.


Your patients may be uncertain about biosimilars. Yet, they trust you. You can help them understand that biosimilars are safe and effective. Patients can expect the same health outcomes if you prescribe or recommend a biosimilar instead of its reference product. Biosimilars can also save patients money as they often pay less out-of-pocket. As trusted advisors, physicians and pharmacists should recommend biosimilar use. Start a conversation with patients to answer their questions and build their trust.

Biosimilar pipeline report

This reference guide is a useful tool to visualize and understand the current product landscape and potential future of this emerging market. 
Biosimilar Pipeline Landscape Report

Resources and education

Access to Biosimilars via GPO


FDA Curriculum Materials for Biosimilars 

The Center for Biosimilars

Biosimilars offer savings and access for U.S. patients
The US Biosimilar Industry

AP News

FDA allows automatic ‘generic’ swap for brand-name insulin

Biosimilars Council, a Division of AAM 

Biosimilars 101

FDA guidance on approved Biosimilars on the market

FDA guidance and information on biosimilars

Our network of provider and GPO solutions 

Our market-leading specialty GPOs are comprised of a collective purchasing power that is unrivaled in the industry. Our GPO services—including thought leadership from the largest and most sophisticated community practices—deliver the strongest, most consistent contract performance in the industry, resulting in an engaged physician-led membership. We generate results for our members with the combined value of our relationships with leading manufacturers, our expertise in industry trends and our diverse contract portfolios.

Featured capabilities

ION Solutions

As the largest oncology-specific GPO and physician service organization, ION Solutions is the preferred strategic partner for community oncology practices nationwide. In addition to giving you access to the most advanced therapies at competitive contract rates, our experts take pride in helping member practices tap the potential within their business. Whether you're interested in uncovering new clinical and operational efficiencies, opening new lines of revenue, or need support navigating the transition to value-based reimbursement—we'll be there to help you, every step of the way.

Specialty Advancement Network

The Specialty Advancement Network (SAN) is built is serve an unmet need in the market, providing recognizable GPO services, like contract administration and educational programming, to hospitals and health systems. Our contracting strategy helps health systems increase access through contracted pricing that makes specialty medications more affordable. Our network is strategically limited to institutions that want to participate in performance-based contracting across specialty-branded medication administered by IV infusion, injection, or select oral medications. 

INN & IPN Solutions

Being one of the longest-standing specialty GPOs in the country means we generate results for our members. With the combined value of our relationships with leading manufacturers, our expertise in industry trends and our diverse contract portfolio, we offer unrivaled collective purchasing power and competitive contracts to specialty practices. Whether you're interested in uncovering new clinical and operational efficiencies, opening new lines of revenue, or need support navigating the transition to value-based reimbursement—we'll be there to help you, every step of the way.

Healthcare providers are integral to the health of people and communities 

At AmerisourceBergen and through our global family of companies, we believe in accessible care in the most appropriate setting to meet the needs of the patient. This is why we serve all sites of care. 

Long term care pharmacy

Your pharmacy plays a key role in the lives of your patients and the strength of your community. That’s why we offer services and programs that go the distance for you. That way, you can go the distance for your patients

Independent pharmacy

We know that no two independent pharmacies are exactly the same. That’s why we create a custom plan that works just for you. From distribution to rebates, our ordering system to program support, we always put your practice’s success first.

Specialty physician practices

We empower physician practices to deliver quality patient care today and prepare for the challenges of tomorrow. From access to life changing medicines, to actionable data insights and marketing-leading specialty expertise, we build partnership that help practices thrive.

Hospitals and health systems

We help health systems succeed in today's rapidly evolving healthcare environment. In addition to our core distribution services, we offer a broad portfolio of solutions to improve your health system's business performance, safety, and patient experience.

Large retail pharmacy

Whether it's optimizing business processes, adding patient services, or finding new revenue streams, our team is ready to help transform your pharmacy into a high-performance operation with best-in-class patient care.

Additional Insights

barriers to biosimilar adoption


Why biopharma companies must understand barriers to biosimilar adoption

May 2022



Biosimilars pipeline report: A guide for understanding the growing market

April 2022


Podcast: Insulin biosimilars part 2

August 2021

Connect with an expert

Find out more about how AmerisourceBergen can support your product or practice as the biosimilars market in the U.S. expands.